Aslani, Nikka M.
HRN: 21-81-63 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/20/2022
CEFUROXIME 750MG (VIAL)
11/20/2022
11/27/2022
IV
375mg
Q8
Pneumonia
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes